The global pharmaceutical industry's revenue is increasingly concentrated in a handful of high-value drug classes, with oncology, diabetes/obesity treatments and immunology leading the charge. According to estimates from Statista Market Insights, cancer drugs alone generated over $217 billion last year, making oncology the largest therapeutic segment, driving nearly one-fifth (18 percent) of all pharmaceutical sales. Antidiabetic medicines rank second, with estimated sales of over $85 billion in 2025, contributing 7 percent to global market revenues.
Some of the top-grossing drugs include Merck's Keytruda, an immunotherapy for multiple cancers with almost $30 billion in revenue in 2024, as well as Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro, used for diabetes treatment and weight loss, and bringing in between $10-20 billion annually for their respective parent companies.
